State-of-the-art Review: Interventional Onco-Cardiology

Analysis of Competing Risks of Causes of Death in Cancer Patients from Golestan, Iran over Twelve Years (2004-2016)

“…chemotherapy) may increase the risk for cardiaotoxity and will consequently increase the risk of cardiovascular diseases and cardiovascular mortalities in cancer patients (Patnaik et al, 2011;Curigliano et al, 2016;Abdel-Qadir et al, 2017;Abdel-Rahman, 2017;Sturgeon et al, 2019). Therefore, patients with diagnosed cancer are at high risk for cardiovascular disease and should be followed up with cardiologist along with oncologist (Pushparaji et al, 2020;Stoltzfus et al, 2020).…”

Partial Reversal of Coronary Stenosis with Intravenous Hydrogen and Oxygen Nanobubble Administration: A Case Report

“…Moreover, the treatment of CAD in special populations, such as cancer patients, has highlighted the importance of individualised care plans, taking into consideration the unique risks and benefits of each treatment modality [10]. In conclusion, the choice between angioplasty with stent placement and CABG for the treatment of coronary stenosis is complex and must be tailored to the individual patient's needs, based on a thorough assessment of the clinical and anatomical factors, as well as the patient's preferences and expected outcomes [28].…”

Structural Transcatheter Cardiac Interventions in the Cardio-Oncology Population

“…The second is functional MR caused by underlying dilated cardiomyopathy (CMY). While radiation therapy can lead to myocardial fibrosis and ultimately cardiomyopathy through similar mechanisms as described previously, multiple traditional chemotherapeutic agents can cause ischemic and non-ischemic CMY [2,4,8]. Additionally, immune checkpoint inhibitors (ICIs) have been shown to cause cardiovascular adverse events in at least 2% of patients, with CMY and myocarditis being among the most concerning [5].…”

“…Cardio-oncology patients pose unique and often difficult management dilemmas when being evaluated for cardiac surgery. The operative risk in this patient population is historically thought to be elevated due to a number of anatomic and physiologic factors including coagulopathy, immunosuppression (bone marrow insufficiency, impaired T cell function, cytokine dysregulation), mediastinal fibrosis due to prior cancer-related mediastinal surgeries, or radiation [4,7,8]. Additionally, cardiopulmonary bypass (CPB) is known to directly damage all cell lines, thus further exacerbating malignancy-related cytopenia and directly increasing postoperative bleeding risk.…”

“…For instance, longitudinal studies in pediatric cancer patients have shown that 15-25 years after initial cancer diagnosis, there is an 8.2-fold higher rate of cardiac death compared with age-and sex-matched national averages [2•]. There are three principal causes for this association: (1) cancer and CVD share many similar risk factors such as smoking, obesity, and advanced age; [3,4] (2) given the overall improved survival of patients undergoing cancer therapy as noted above, de novo CVD develops as a normal process in this aging population; and (3) cancer therapies including radiation, traditional chemotherapies, and newer novel targeted therapies can cause significant cardiovascular complications. These complications include heart failure, myocardial ischemia, arrhythmias, valvular heart disease, thromboembolism, hypertension, pulmonary hypertension, and pericardial diseases [3,5].…”